Granite Investment Advisors’s West Pharmaceutical WST Stock Holding History

Granite Investment Advisors’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$2.69M	Buy	+6,348	New	+$2.68M	0.44%	82

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Granite Investment Advisors's WST Position: Q3 2021 in Review

Granite Investment Advisors opened a new position in West Pharmaceutical (WST) in Q3 2021: 6,348 shares worth $2.69M. The stake represents 0.44% of the portfolio and ranks #82 among its holdings.

669 funds tracked by Wall St. Rank hold WST as of Q3 2021.

Granite Investment Advisors held 6,348 shares of West Pharmaceutical worth $2.69M as of Q3 2021.
West Pharmaceutical was a new Granite Investment Advisors position in Q3 2021.
West Pharmaceutical made up 0.44% of Granite Investment Advisors's portfolio in Q3 2021, its #82 holding.
669 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2021.

Based on Granite Investment Advisors's 13F filing for Q3 2021, filed 8 Nov 2021.